Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.

Silva KL, de Souza PS, Nestal de Moraes G, Moellmann-Coelho A, Vasconcelos Fda C, Maia RC.

Leuk Res. 2013 Oct;37(10):1350-8. doi: 10.1016/j.leukres.2013.06.014. Epub 2013 Jul 25.

2.

Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells.

Bernardo PS, Reis FR, Maia RC.

Leuk Res. 2012 Dec;36(12):1510-6. doi: 10.1016/j.leukres.2012.08.014. Epub 2012 Sep 10.

3.

P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells.

Souza PS, Vasconcelos FC, De Souza Reis FR, Nestal De Moraes G, Maia RC.

Int J Oncol. 2011 Oct;39(4):925-33. doi: 10.3892/ijo.2011.1103. Epub 2011 Jun 28.

PMID:
21720708
4.

Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients.

Vasconcelos FC, Nestal de Moraes G, Moellmann-Coelho A, Maia RC.

Leuk Res. 2013 Dec;37(12):1711-8. doi: 10.1016/j.leukres.2013.09.021. Epub 2013 Sep 29.

PMID:
24210993
5.

ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.

Airiau K, Mahon FX, Josselin M, Jeanneteau M, Turcq B, Belloc F.

Exp Hematol. 2012 May;40(5):367-78.e2. doi: 10.1016/j.exphem.2012.01.004. Epub 2012 Jan 10.

PMID:
22240609
6.

Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients.

Vasconcelos FC, Silva KL, Souza PS, Silva LF, Moellmann-Coelho A, Klumb CE, Maia RC.

Cytometry B Clin Cytom. 2011 May;80(3):158-66. doi: 10.1002/cyto.b.20580. Epub 2010 Dec 2.

7.

Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.

Yamada O, Ozaki K, Furukawa T, Machida M, Wang YH, Motoji T, Mitsuishi T, Akiyama M, Yamada H, Kawauchi K, Matsuoka R.

Cell Signal. 2011 Jul;23(7):1119-27. doi: 10.1016/j.cellsig.2011.02.005. Epub 2011 Feb 26.

PMID:
21356308
8.

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV.

Blood. 2003 Mar 15;101(6):2368-73.

9.
10.

Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib.

Seca H, Lima RT, Guimarães JE, Helena Vasconcelos M.

Hematology. 2011 Mar;16(2):100-8. doi: 10.1179/102453311X12940641877803.

PMID:
21418741
11.

[Regulation of wild type PTEN gene on Survivin, Xiap and Smac in chronic leukemia cells].

Cheng ZY, Wan JS, Wang YL, Liang LQ, Liang WT, Mu J, Lu X, Pan L.

Zhonghua Yi Xue Za Zhi. 2011 Nov 1;91(40):2868-72. Chinese.

PMID:
22333553
12.

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.

Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlägel U, von Bonin M, Pursche S, Bergemann T, Ehninger G, Schleyer E.

Leukemia. 2004 Mar;18(3):401-8.

PMID:
14724652
13.

[Effect of bortezomib on reverse multidrug resistance and XIAP expression in imatinib-resistant primary cells of chronic myeloid leukemia in blastic crisis].

Zhao J, Ma LM.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Aug;21(4):899-904. doi: 10.7534/j.issn.1009-2137.2013.04.017. Chinese.

PMID:
23998582
14.

Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib.

Stromskaya TP, Rybalkina EY, Kruglov SS, Zabotina TN, Mechetner EB, Turkina AG, Stavrovskaya AA.

Biochemistry (Mosc). 2008 Jan;73(1):29-37.

PMID:
18294126
15.
16.

Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.

Ma D, Fang Q, Wang P, Gao R, Wu W, Lu T, Cao L, Hu X, Wang J.

J Biol Chem. 2015 May 15;290(20):12558-71. doi: 10.1074/jbc.M114.626960. Epub 2015 Mar 23.

17.

Imatinib resistance in multidrug-resistant K562 human leukemic cells.

Assef Y, Rubio F, Coló G, del Mónaco S, Costas MA, Kotsias BA.

Leuk Res. 2009 May;33(5):710-6. doi: 10.1016/j.leukres.2008.09.024. Epub 2008 Nov 1.

PMID:
18977528
18.

Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.

Yamakawa Y, Hamada A, Uchida T, Sato D, Yuki M, Hayashi M, Kawaguchi T, Saito H.

Biol Pharm Bull. 2014;37(8):1330-5.

19.

Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro.

Ferrao PT, Frost MJ, Siah SP, Ashman LK.

Blood. 2003 Dec 15;102(13):4499-503. Epub 2003 Jul 24.

20.

Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.

Wang W, Zhang J, Li Y, Yang X, He Y, Li T, Ren F, Zhang J, Lin R.

Cancer Lett. 2015 Jan 28;356(2 Pt B):791-9. doi: 10.1016/j.canlet.2014.10.033. Epub 2014 Oct 31.

PMID:
25449787

Supplemental Content

Support Center